Literature DB >> 19854350

The function, proteolytic processing, and histopathology of Met in cancer.

Jason A Hanna1, Jennifer Bordeaux, David L Rimm, Seema Agarwal.   

Abstract

The hepatocyte growth factor (HGF) and its receptor, the Met receptor tyrosine kinase, form a signaling network promoting cell proliferation, invasion, and survival in normal and cancer cells. Improper regulation of this pathway is attributed to many cancer types through overexpression, activating mutations, or autocrine loop formation. Many studies describe the localization of Met as membranous/cytoplasmic, but some studies using antibodies targeted to the C-terminal domain of Met report nuclear localization. This chapter seeks to highlight the histopathology and expression of Met in cancer and its association with clinicopathological characteristics. We also discuss recent studies of the proteolytic processing of Met and effects of the processing on the subcellular localization of Met. Finally, we comment on Met as a therapeutic target for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854350     DOI: 10.1016/S0065-230X(09)03001-2

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  10 in total

1.  Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling.

Authors:  Yang Yang; Aimin Zang; Youchao Jia; Yanhong Shang; Zhuoqi Zhang; Kun Ge; Jinchao Zhang; Wufang Fan; Bei Wang
Journal:  Oncol Lett       Date:  2016-07-06       Impact factor: 2.967

2.  γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells.

Authors:  N M Ayoub; S V Bachawal; P W Sylvester
Journal:  Cell Prolif       Date:  2011-10-04       Impact factor: 6.831

Review 3.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

Review 4.  Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

Authors:  Flavia Zita Francies; Rodney Hull; Richard Khanyile; Zodwa Dlamini
Journal:  Am J Cancer Res       Date:  2020-05-01       Impact factor: 5.942

5.  c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target.

Authors:  Yohei Ozawa; Yasuhiro Nakamura; Fumiyoshi Fujishima; Saulo J A Felizola; Kenichiro Takeda; Hiroshi Okamoto; Ken Ito; Hirotaka Ishida; Takuro Konno; Takashi Kamei; Go Miyata; Noriaki Ohuchi; Hironobu Sasano
Journal:  BMC Cancer       Date:  2015-06-03       Impact factor: 4.430

Review 6.  The clinical and functional significance of c-Met in breast cancer: a review.

Authors:  Colan M Ho-Yen; J Louise Jones; Stephanie Kermorgant
Journal:  Breast Cancer Res       Date:  2015-04-08       Impact factor: 6.466

7.  A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling.

Authors:  W Li; M Hu; C Wang; H Lu; F Chen; J Xu; Y Shang; F Wang; J Qin; Q Yan; B J Krueger; R Renne; S-J Gao; C Lu
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

8.  Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.

Authors:  Fangjin Huang; Zhaoxuan Ma; Sara Pollan; Xiaopu Yuan; Steven Swartwood; Arkadiusz Gertych; Maria Rodriguez; Jayati Mallick; Sanica Bhele; Maha Guindi; Deepti Dhall; Ann E Walts; Shikha Bose; Mariza de Peralta Venturina; Alberto M Marchevsky; Daniel J Luthringer; Stephan M Feller; Benjamin Berman; Michael R Freeman; W Gregory Alvord; George Vande Woude; Mahul B Amin; Beatrice S Knudsen
Journal:  J Pathol Clin Res       Date:  2016-07-01

9.  Circular RNA LPAR3 sponges microRNA-198 to facilitate esophageal cancer migration, invasion, and metastasis.

Authors:  Yijun Shi; Na Fang; Yadong Li; Zizhang Guo; Wei Jiang; Yaozhou He; Zijian Ma; Yijiang Chen
Journal:  Cancer Sci       Date:  2020-07-15       Impact factor: 6.716

10.  Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Authors:  Chen-Yu Hu; Xiang-Ming Xu; Bo Hong; Zhi-Gang Wu; Yun Qian; Tian-Hao Weng; Yi-Zhi Liu; Tao-Ming Tang; Ming-Hai Wang; Hang-Ping Yao
Journal:  Front Oncol       Date:  2019-12-05       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.